<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2812">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478256</url>
  </required_header>
  <id_info>
    <org_study_id>SAIRB-11-0007</org_study_id>
    <nct_id>NCT01478256</nct_id>
  </id_info>
  <brief_title>Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis</brief_title>
  <official_title>A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John, George, M.D.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>John, George, M.D.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at the improvements in signs and symptoms in patients with inflammation of
      the lids, blepharitis, using two different FDA approved topical antibiotic agents,
      Besifloxocin and Erythromycin. It also evaluates the bacterial cultures in these patients
      for microbiologic evidence of improvement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot project involving thirty patients with a specific form of inflammtion of the
      lids called anterior blepharitis. The patients are graded for their signs a symptoms and
      then randomized to receive either topical Besifloxocin or Erythromycin in addition to
      standard lid hygiene measures. All patients have cultures of their eyelids performed prior
      to initiating therapy and are followed for four weeks. The antibiotics are used for two
      weeks following which repeat cultures of the lids are obtained. The patients are followed
      for one additional week to ensure that there is no recurrence of their symptoms once the
      antibiotics are discontinued.

      Only adult patients (age 18-100)and women who are not of child bearing potential are
      included in this study. Then patients have to have symptoms and signs of the disease,
      blepharitis. Patient who are on unstable antibiotic or steroid regimens and those who cannot
      discontinue contact lens use are not included in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Signs and Symptoms of Blepharitis</measure>
    <time_frame>Four weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics</measure>
    <time_frame>Three weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>Besifloxocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use of topical besifloxocin to treat acute blepharitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical Erythromycin ointment for treatment of acute blepharitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>Topical erythromycin ointment twice a day</description>
    <arm_group_label>Erythromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxocin</intervention_name>
    <description>Topical Besifloxocin twice a day</description>
    <arm_group_label>Besifloxocin</arm_group_label>
    <other_name>Besivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Acute blepharitis, age 18-100, Signs and symptoms of blepharitis -

        Exclusion Criteria: women of child bearing potential, eye surgery within three months of
        study, contact lens wear, use of topical or antibacterial agents in past two weeks, use of
        topical or oral steroids in past two weeks unless stable dosage
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>George John, M.D.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>November 21, 2011</firstreceived_date>
  <firstreceived_results_date>April 9, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John, George, M.D.</investigator_affiliation>
    <investigator_full_name>George John, M.D.</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>blepharitis</keyword>
  <keyword>topical erythromycin</keyword>
  <keyword>topical besifloxocin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Blepharitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Besifloxocin</title>
          <description>Use of topical besifloxocin twice a day to treat acute blepharitis</description>
        </group>
        <group group_id="P2">
          <title>Erythromycin</title>
          <description>Topical Erythromycin ointment twice a day for treatment of acute blepharitis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Besifloxocin</title>
          <description>Use of topical besifloxocin twice a day to treat acute blepharitis</description>
        </group>
        <group group_id="B2">
          <title>Erythromycin</title>
          <description>Topical Erythromycin ointment twice a day for treatment of acute blepharitis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48" spread="10"/>
                <measurement group_id="B2" value="50" spread="12"/>
                <measurement group_id="B3" value="49" spread="11"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Signs and Symptoms of Blepharitis</title>
        <description>Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics</description>
        <time_frame>Four weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Besifloxocin</title>
            <description>Use of topical besifloxocin to treat acute blepharitis</description>
          </group>
          <group group_id="O2">
            <title>Erythromycin</title>
            <description>Topical Erythromycin ointment for treatment of acute blepharitis</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Improvement in Signs and Symptoms of Blepharitis</title>
            <description>Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics</title>
        <description>Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis</description>
        <time_frame>Three weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Besifloxocin</title>
            <description>Use of topical besifloxocin twice a day to treat acute blepharitis</description>
          </group>
          <group group_id="O2">
            <title>Erythromycin</title>
            <description>Topical Erythromycin ointment twice a day for treatment of acute blepharitis</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics</title>
            <description>Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Besifloxocin</title>
          <description>Use of topical besifloxocin to treat acute blepharitis</description>
        </group>
        <group group_id="E2">
          <title>Erythromycin</title>
          <description>Topical Erythromycin ointment for treatment of acute blepharitis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>George John</name_or_title>
      <organization>George John MD</organization>
      <phone>5028949757</phone>
      <email>grjohn777@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
